Frequency of Multiple Sclerosis in Valle d'Aosta, 1971–1985Sironi L. · Mamoli A. · D'Alessandro G. · Camerlingo M. · Bottachi E.
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
According to studies done before 1980, the multiple sclerosis (MS) prevalence rate in Italy ranged from 7.2 to 27.1 cases per 100,000 inhabitants. More recent work has consistently put the MS prevalence rate to over 30 cases per 100,000 inhabitants. If these recent data are confirmed in the future, Italy can no longer be regarded as a country at low risk for MS, but must be included among the medium-high risk countries of continental Europe. We report the results of a prevalence and incidence survey conducted in Valle d''Aosta, a region whose special features make it an excellent epidemiological model. The mean annual incidence was 2.1 and on December 31, 1985, the prevalence was 39 cases per 100,000 inhabitants. These results confirm that the incidence and prevalence rate of MS in Valle d''Aosta is close to that of areas at high-risk for MS.
© 1991 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.